Long-acting GLP-1 receptor agonist featuring a human GLP-1 analog fused to a modified Fc domain. Provides sustained appetite suppression and glycemic control with convenient weekly dosing. Developed as a next-generation GLP-1 therapy.
Inject SubQ once weekly, same day each week. Titrate from 1.5mg. Novel Fc-fusion technology for extended half-life.
Log doses, calculate reconstitution, set reminders, and get AI guidance for BPI-3016.
Start Free Trial